Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis.

Background: Not all pediatric patients with relapsing-remitting multiple sclerosis (MS) may respond to traditional disease-modifying therapies. Natalizumab has been shown to be effective but is currently only approved in adults.

Objective: To analyze the safety and efficacy of natalizumab in patients under 18 years of age diagnosed with MS.